Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
92.68%
-
Total 13F principal
-
$214,232,388
-
Principal change
-
+$4,118,550
-
Total reported market value
-
$199,159,544
-
Number of holders
-
22
-
Value change
-
+$1,523,738
-
Number of buys
-
14
-
Number of sells
-
14
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q3 2021
As of 30 Sep 2021,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$214,232,388
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, DeepCurrents Investment Group LLC, BAUPOST GROUP LLC/MA, HBK INVESTMENTS L P, AVIVA PLC, Maven Securities LTD, Aequim Alternative Investments LP, Verition Fund Management LLC, TENOR CAPITAL MANAGEMENT Co., L.P., and Balyasny Asset Management LLC.
This page lists
22
institutional bondholders reporting positions
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.